TBG Diagnostics (Australia) Profile |
0.16 |
|
TBG Diagnostics Limited Risk Profiles
| Mean Deviation | 3.09 | ||
| Standard Deviation | 6.71 | ||
| Variance | 45.02 | ||
| Risk Adjusted Performance | 0.088921 |
Key Fundamentals
| Current Valuation | 9.63 M | ||
| Shares Outstanding | 124.86 M | ||
| Revenue | 3.44 M |
TBG Diagnostics Against Markets
PGL
TBG Diagnostics Limited, a biotechnology company, focuses on the development, manufacture, and marketing of nucleic acid test kits. more
| Name | TBG Diagnostics Limited |
| CEO - Pharmasynth | Leslie TillackView All |
| Macroaxis Advice | |
| Instrument | Australia Stock View All |
| Business Address | Darra, QLD |
| Exchange | Australian Securities Exchange |
| Benchmark | DOW |
| Website | www.tbgbio.com |
| Contact Number | 61 7 3273 9133 |
| Currency | null |
Other Suggestions
View Currently Related Equities
Diversify with TBG Diagnostics Limited
Build Optimal Portfolios
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add TBG Diagnostics Limited to your portfolio
Directors
TBG Diagnostics Corporate Directors
| Fleur Lankesheer Director - Business Development and Legal | |
| Keith Dredge Director of Drug Development, Ph.D | |
| YuZen Cheng Director |
Additionally take a look at Your Equity Center. Please also try Crypto Portfolio Optimizer module to optimize portfolio of digital coins and token across multiple currency and exchanges.